JAMA Network
About The Study: This cross-sectional study of privately insured patients found a more than 2-fold increase in use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications from 2022 to 2023, with a 25.6% decrease in the rate of metabolic bariatric surgery during the same period. Our results provide a national contemporaneous estimate of the decline in metabolic bariatric surgery associated with the era of GLP-1 RAs.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
